Cargando…

Prognostic significance of frailty status in patients with primary lung cancer

Lung cancer has one of the highest morbidity and mortality rates in the world. Frailty is common in many countries and is a major cause of premature functional decline and premature death in older adults, and may affect the treatment and prognosis of lung cancer patients. To investigate the predicti...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Kai, She, Quan, Li, Min, Zhao, Hongye, Zhao, Weihong, Chen, Bo, Wu, Jianqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878966/
https://www.ncbi.nlm.nih.gov/pubmed/36698160
http://dx.doi.org/10.1186/s12877-023-03765-w
_version_ 1784878601571663872
author Wang, Kai
She, Quan
Li, Min
Zhao, Hongye
Zhao, Weihong
Chen, Bo
Wu, Jianqing
author_facet Wang, Kai
She, Quan
Li, Min
Zhao, Hongye
Zhao, Weihong
Chen, Bo
Wu, Jianqing
author_sort Wang, Kai
collection PubMed
description Lung cancer has one of the highest morbidity and mortality rates in the world. Frailty is common in many countries and is a major cause of premature functional decline and premature death in older adults, and may affect the treatment and prognosis of lung cancer patients. To investigate the predictive value of frailty at diagnosis on all-cause mortality in lung cancer patients, this study retrospectively collected and analysed clinical information on lung cancer patients from 2015–2018. A total of 1667 patients with primary lung cancer were finally included in this study. The median follow-up time of patients was 650 (493, 1001.5) days. A total of 297(17.8%) patients had FI-LAB(the frailty index based on laboratory test) status of frail at the moment of diagnosis and the all-cause mortality rate for all patients was 61.1% (1018/1667). In a univariate model, we found a higher total all-cause mortality risk in frail patients (frail vs. robust, HR(hazard ratio) = 1.616, 95% CI(confidence interval) = 1.349,1.936), after balancing other variables combined into model 1 to model 6. The results were analyzed visually using ROC(Receiver operating characteristic) curves with nomogram and the AUC values ranged from 0.866–0.874. The final inclusion of age, TNM stage, CCI(Charlson comorbidity index) score, surgery history and chemotherapy into a multifactorial model balanced the predictive power of frailty grading on all-cause mortality. The study showed that for lung cancer patients, the higher the level of frailty at diagnosis, the higher the risk of all-cause mortality. In the context of widespread electronic medical records in hospitals, it is convenient and feasible to use FI-LAB to assess the prognosis of lung cancer patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12877-023-03765-w.
format Online
Article
Text
id pubmed-9878966
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98789662023-01-27 Prognostic significance of frailty status in patients with primary lung cancer Wang, Kai She, Quan Li, Min Zhao, Hongye Zhao, Weihong Chen, Bo Wu, Jianqing BMC Geriatr Research Lung cancer has one of the highest morbidity and mortality rates in the world. Frailty is common in many countries and is a major cause of premature functional decline and premature death in older adults, and may affect the treatment and prognosis of lung cancer patients. To investigate the predictive value of frailty at diagnosis on all-cause mortality in lung cancer patients, this study retrospectively collected and analysed clinical information on lung cancer patients from 2015–2018. A total of 1667 patients with primary lung cancer were finally included in this study. The median follow-up time of patients was 650 (493, 1001.5) days. A total of 297(17.8%) patients had FI-LAB(the frailty index based on laboratory test) status of frail at the moment of diagnosis and the all-cause mortality rate for all patients was 61.1% (1018/1667). In a univariate model, we found a higher total all-cause mortality risk in frail patients (frail vs. robust, HR(hazard ratio) = 1.616, 95% CI(confidence interval) = 1.349,1.936), after balancing other variables combined into model 1 to model 6. The results were analyzed visually using ROC(Receiver operating characteristic) curves with nomogram and the AUC values ranged from 0.866–0.874. The final inclusion of age, TNM stage, CCI(Charlson comorbidity index) score, surgery history and chemotherapy into a multifactorial model balanced the predictive power of frailty grading on all-cause mortality. The study showed that for lung cancer patients, the higher the level of frailty at diagnosis, the higher the risk of all-cause mortality. In the context of widespread electronic medical records in hospitals, it is convenient and feasible to use FI-LAB to assess the prognosis of lung cancer patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12877-023-03765-w. BioMed Central 2023-01-25 /pmc/articles/PMC9878966/ /pubmed/36698160 http://dx.doi.org/10.1186/s12877-023-03765-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Kai
She, Quan
Li, Min
Zhao, Hongye
Zhao, Weihong
Chen, Bo
Wu, Jianqing
Prognostic significance of frailty status in patients with primary lung cancer
title Prognostic significance of frailty status in patients with primary lung cancer
title_full Prognostic significance of frailty status in patients with primary lung cancer
title_fullStr Prognostic significance of frailty status in patients with primary lung cancer
title_full_unstemmed Prognostic significance of frailty status in patients with primary lung cancer
title_short Prognostic significance of frailty status in patients with primary lung cancer
title_sort prognostic significance of frailty status in patients with primary lung cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878966/
https://www.ncbi.nlm.nih.gov/pubmed/36698160
http://dx.doi.org/10.1186/s12877-023-03765-w
work_keys_str_mv AT wangkai prognosticsignificanceoffrailtystatusinpatientswithprimarylungcancer
AT shequan prognosticsignificanceoffrailtystatusinpatientswithprimarylungcancer
AT limin prognosticsignificanceoffrailtystatusinpatientswithprimarylungcancer
AT zhaohongye prognosticsignificanceoffrailtystatusinpatientswithprimarylungcancer
AT zhaoweihong prognosticsignificanceoffrailtystatusinpatientswithprimarylungcancer
AT chenbo prognosticsignificanceoffrailtystatusinpatientswithprimarylungcancer
AT wujianqing prognosticsignificanceoffrailtystatusinpatientswithprimarylungcancer